Moreover, real-time cellular analysis (RTCA) corroborated the tumor-lytic potential of FCRL5 CAR-T cells in engineered FCRL5-overexpressing HeLa cells (HeLa-FCRL5) (Fig. 5i, Supplementary Fig. S4g). Here, FCRL5 is linked to neoplasm.